 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H22N4O2 |
| Molar mass | 290.367 g·mol−1 |
| 3D model (JSmol) | |
| |
Cartazolate (SQ-65,396) is adrug of thepyrazolopyridine class. It acts as aGABAA receptorpositive allosteric modulator at thebarbituratebinding site of the complex and hasanxiolytic effects in animals.[1][2][3][4] It is also known to act as anadenosineantagonist at theA1 andA2 subtypes and as aphosphodiesterase inhibitor.[5][6] Cartazolate was tested in humanclinical trials and was found to be efficacious foranxiety but was never marketed.[7] It was developed by a team at E.R. Squibb and Sons in the 1970s.[8]
